The Europe-wide Falsified Medicines Directive 2011/62/EU coming into force in February 2019 requires all pharmaceutical manufacturers to mark their prescription medicine packaging with a serial number and an additional tamper protection device.
Covert-Hologram Seal manufactured by Schreiner Medipharm provides a wide range of features which abide to the EU directives:
1. Reliable First-Opening Indication,
2. Tamper Evidence,
3. Irreversible, Holographic Effect, and
4. Counterfeiting Protection.
The innovative Covert-Hologram Seal is transparent, inconspicuous and thus appears like a simple packaging seal. However, the first time the seal is opened, an invisible effect becomes visible. A hologram emerges that shows various inscriptions and design elements in different colors depending on the viewing angle. The holographic effect is irreversible and the seal’s fully transparent original condition cannot be restored. Thus, manufacturers, suppliers, and patients can tell at first glance if the packaging has been previously opened or if the medicine is an originally packaged product. In addition, Covert anti-counterfeiting features embedded in the specialty closure seal add extra security.
Thus, the Covert-Hologram Seal effectively combines the reliable first-opening indication required by the EU Directive with additional counterfeiting protection in a single seal, enhancing security throughout the entire supply chain.
Comments
This directive will really
This directive will really beneficial for the pharmaceutical industry bad definitely bring a positive change .